We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

418 hedge funds and large institutions have $14.8B invested in BioMarin Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 160 increasing their positions, 133 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 47

20% more repeat investments, than reductions

Existing positions increased: 160 | Existing positions reduced: 133

6% more capital invested

Capital invested by funds: $14B → $14.8B (+$809M)

9% more call options, than puts

Call options by funds: $82.3M | Put options by funds: $75.7M

1% more funds holding

Funds holding: 414 → 418 (+4)

0.69% less ownership

Funds ownership: 98.49% → 97.8% (-0.69%)

18% less funds holding in top 10

Funds holding in top 10: 11 → 9 (-2)

Holders
418
Holders Change
+4
Holders Change %
+0.97%
% of All Funds
10.41%
Holding in Top 10
9
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-18.18%
% of All Funds
0.22%
New
62
Increased
160
Reduced
133
Closed
47
Calls
$82.3M
Puts
$75.7M
Net Calls
+$6.61M
Net Calls Change
+$11.7M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$971M
2
Primecap Management
Primecap Management
California
+$73.5M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$72.3M
4
Jennison Associates
Jennison Associates
New York
+$56.1M
5
ClearBridge Investments
ClearBridge Investments
New York
+$46M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$91.7M
2
HM
HealthCor Management
New York
-$64.2M
3
Viking Global Investors
Viking Global Investors
Connecticut
-$46.5M
4
Victory Capital Management
Victory Capital Management
Texas
-$44.4M
5
Marshall Wace
Marshall Wace
United Kingdom
-$37M
Name Holding Trade Value Shares
Change 		Change in
Stake
MOACM
351
Mutual of America Capital Management
New York
$181K +$30.6K +344 +20%
SEC
352
Seven Eight Capital
New York
$176K +$178K +2,000 New
Toronto Dominion Bank
353
Toronto Dominion Bank
Ontario, Canada
$165K +$35.7K +401 +27%
CS
354
Credential Securities
$153K +$155K +1,747 New
GXMC
355
Global X Management Company
New York
$145K +$55.1K +619 +60%
LIA
356
LS Investment Advisors
Michigan
$127K – – –
CAW
357
Cornerstone Advisors (Washington)
Washington
$121K +$356 +4 +0.3%
NAMA
358
Nikko Asset Management Americas
New York
$114K +$116K +1,300 New
IPC
359
Independent Portfolio Consultants
Florida
$101K -$10.2K -115 -9%
PA
360
Parallel Advisors
California
$100K +$11.1K +125 +14%
LWCFA
361
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$97K – – –
TFO
362
Tarbox Family Office
California
$90K – – –
FIM
363
Foresters Investment Management
New York
$73K +$73.5K +826 New
CBOA
364
Commonwealth Bank of Australia
Australia
$70K +$10.9K +123 +18%
CLM
365
ClearBridge LLC (Maryland)
Maryland
$69K – – –
IIC
366
Integrated Investment Consultants
Michigan
$64K – – –
Northwestern Mutual Wealth Management
367
Northwestern Mutual Wealth Management
Wisconsin
$61K -$116K -1,306 -65%
Korea Investment Corp
368
Korea Investment Corp
South Korea
$57K +$40.3K +453 +224%
HFM
369
Hartford Financial Management
Connecticut
$53K +$54.3K +610 New
SIM
370
Sonora Investment Management
Arizona
$52.7K – – –
PCP
371
Proficio Capital Partners
Massachusetts
$49K +$32.1K +361 +190%
FPFS
372
First Personal Financial Services
North Carolina
$44K – – –
IA
373
IFP Advisors
Florida
$40K -$2.22K -25 -5%
DADC
374
D.A. Davidson & Co
Montana
$39K +$5.78K +65 +17%
TJHA
375
Thomas J. Herzfeld Advisors
Florida
$35K – – –
13 14
15
16 17

BMRN Hedge Fund Activity: Q1 2017 in Review

418 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q1 2017, worth a combined $14.8B — up 5.8% from $14B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new BMRN positions and 47 closed out — a net gain of 15 holders — while 160 added to existing stakes and 133 trimmed.

The largest buyer was BlackRock, adding an estimated $971M. The largest seller was JP Morgan Chase, cutting an estimated $91.7M.

  • 418 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q1 2017, up from 414 in Q4 2016.
  • Funds reported $14.8B of BioMarin Pharmaceuticals stock for Q1 2017, up 5.8% quarter-over-quarter.
  • 62 funds opened new BioMarin Pharmaceuticals positions in Q1 2017 and 47 closed out, a net change of +15 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $971M added.
  • The largest BioMarin Pharmaceuticals seller in Q1 2017 was JP Morgan Chase, an estimated $91.7M sold.

Based on aggregated 13F filings for Q1 2017.